[1-(trifluoromethyl)cyclobutyl]methyl trifluoromethanesulphonate | 371917-25-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: [1-(trifluoromethyl)cyclobutyl]methyl trifluoromethanesulphonate
• 英文别名: (1-(Trifluoromethyl)cyclobutyl)methyl trifluoromethanesulfonate；[1-(trifluoromethyl)cyclobutyl]methyl trifluoromethanesulfonate
• CAS: 371917-25-8
• 化学式: C₇H₈F₆O₃S
• 分子量: 286.195
• InChiKey: OWTHBRNPISTGCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  [1-(trifluoromethyl)cyclobutyl]methyl trifluoromethanesulphonate 在 四丁基氟化铵 作用下， 以 乙醚 为溶剂， 反应 12.0h， 以54%的产率得到1-Fluoromethyl-1-(trifluoromethyl)cyclobutane
  参考文献：
  名称：

  Routes from 1,1-cycloalkanedicarboxylic acids to geminal bis(polyfluoromethyl) substituted carbocycles

  摘要：

  1-Fluoroformyl-1-1(trifluoromethyl)cycloalkanes (1), prepared by treatment of 1,1-cycloalkane-dicarboxylic acids with SF4, were efficiently reduced to 1-hydroxymethyl-1-(trifluoromethyl)-cycloalkanes (2). Routes for the conversion of alcohols 2 to 1-methyl-1-(trifluoromethyl) cycloalkanes (4), 1-fluoromethyl-1-(trifluoromethyl)cycloalkanes (6) and 1-difluoromethyl-1-(trifluoromethyl)cycloalkanes (8), via iodides 3, triflates 5 and aldehydes 7, respectively, were investigated. (C) 2001 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0022-1139(01)00353-0
• 作为产物：
  描述：

  1-(三氟甲基)环丁烷羰基氟化物 在 吡啶 、 lithium aluminium tetrahydride 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 [1-(trifluoromethyl)cyclobutyl]methyl trifluoromethanesulphonate
  参考文献：
  名称：

  Routes from 1,1-cycloalkanedicarboxylic acids to geminal bis(polyfluoromethyl) substituted carbocycles

  摘要：

  1-Fluoroformyl-1-1(trifluoromethyl)cycloalkanes (1), prepared by treatment of 1,1-cycloalkane-dicarboxylic acids with SF4, were efficiently reduced to 1-hydroxymethyl-1-(trifluoromethyl)-cycloalkanes (2). Routes for the conversion of alcohols 2 to 1-methyl-1-(trifluoromethyl) cycloalkanes (4), 1-fluoromethyl-1-(trifluoromethyl)cycloalkanes (6) and 1-difluoromethyl-1-(trifluoromethyl)cycloalkanes (8), via iodides 3, triflates 5 and aldehydes 7, respectively, were investigated. (C) 2001 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0022-1139(01)00353-0

文献信息

• [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2015078374A1

  公开（公告）日：2015-06-04

  The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  这项发明提供了具有一般式I的化合物及其药用盐，其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述，并包含这种化合物的组合物和使用这种化合物和组合物的方法。
• Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160052884A1

  公开（公告）日：2016-02-25

  The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

  这项发明涉及替代的氧代吡啶衍生物及其制备方法，以及它们用于制备用于治疗和/或预防疾病的药物，特别是心血管疾病，优选是血栓性或血栓栓塞性疾病、水肿以及眼科疾病。
• SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
  申请人：GENENTECH, INC.

  公开号：US20150252038A1

  公开（公告）日：2015-09-10

  The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R A , R AA , subscript n, ring A, X 2 , L, subscript m, X 1 , R 1 , R 2 , R 3 , R 4 , R 5 , and R N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compactions.

  本发明提供具有一般式I的化合物及其药学上可接受的盐，其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述，并且包含这些化合物的组合物和使用这些化合物和组合物的方法。
• Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US09434690B2

  公开（公告）日：2016-09-06

  The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

  本发明涉及取代的氧代吡啶衍生物及其制备方法，以及它们用于制备药物治疗和/或预防疾病，特别是心血管疾病，优选血栓性或栓塞性疾病和水肿，以及眼科疾病的用途。
• Substituted oxopyridine derivatives and use thereof cardiovascular disorders
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US10183932B2

  公开（公告）日：2019-01-22

  The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

  本发明涉及取代的氧吡啶衍生物及其制备工艺，还涉及其用于制备治疗和/或预防疾病的药物，尤其是心血管疾病，最好是血栓性或血栓栓塞性疾病和水肿，以及眼科疾病。